MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
University of Pennsylvania
Filadelfia, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Pennsylvania (3)
2019
-
Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma
Journal of Clinical Oncology
2018
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
2014
-
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Biomarker Research, Vol. 2, Núm. 1